Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/16/2024 | $100.00 → $115.00 | Neutral → Buy | BofA Securities |
| 12/16/2024 | $113.00 | Mkt Outperform | JMP Securities |
| 10/7/2024 | $114.00 → $90.00 | Buy → Neutral | BofA Securities |
| 9/22/2023 | $108.00 | Overweight | JP Morgan |
| 6/30/2023 | $138.00 | Buy | BofA Securities |
| 12/14/2021 | $120.00 | Market Perform → Market Outperform | CJS Securities |
| 8/6/2021 | $130.00 → $139.00 | Outperform | Barrington Research |
4 - U S PHYSICAL THERAPY INC /NV (0000885978) (Issuer)
4 - U S PHYSICAL THERAPY INC /NV (0000885978) (Issuer)
BofA Securities upgraded U.S. Physical Therapy from Neutral to Buy and set a new price target of $115.00 from $100.00 previously
JMP Securities initiated coverage of U.S. Physical Therapy with a rating of Mkt Outperform and set a new price target of $113.00
BofA Securities downgraded U.S. Physical Therapy from Buy to Neutral and set a new price target of $90.00 from $114.00 previously
U.S. Physical Therapy, Inc. (the "Company") (NYSE:USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services headquartered in Houston, Texas, today announced a dual listing of its common stock on NYSE Texas, the newly launched fully electronic equities exchange based in Dallas, Texas. U.S. Physical Therapy will maintain its primary listing on the New York Stock Exchange and trade with the same "USPH" ticker symbol on NYSE Texas. Chris Reading, Chairman and Chief Executive Officer, said, "We are honored to join NYSE Texas as a Founding Member and to champion the dynamic growth, energy and grit that define this great state. Being
EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of Dr. Bernard A. Harris, Jr. to its newly-formed Business Advisory Board (BAB). "I am very pleased to welcome Dr. Harris to our new Business Advisory Board," said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology. "As we continue
~Highly Esteemed Growth Strategist and Financial Expert with Decades of Business Acumen~ NEW YORK, Oct. 18, 2022 /PRNewswire/ -- The National Kidney Foundation (NKF) is pleased to announce the appointment of Anne Motsenbocker to its national Board of Directors. We're honored & excited Anne has joined the national board to share her extensive business acumen in board governance.Motsenbocker resides in Dallas, Texas and is a former banker and seasoned board member bringing over 35 years of commercial banking and wealth management expertise due to the numerous roles she held at J